PF-04937319
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the…
Abstract A Css-MRTpo superposition method was devised to predict (retrospectively) oral plasma concentration–time profiles of PF…
Abstract 1. The partial glucokinase activator N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy…
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered…
Glucokinase enhances glucose conversion to glucose‐6‐phosphate, causing glucose‐stimulated insulin secretion from pancreatic…
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF‐04937319, as add‐on…
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl…
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF…